Logo

Pall

People in the News: New Appointments at Fluidigm, Danaher, Guardant Health

Life Sciences, Diagnostics Drive Danaher Q2 Revenues Up 4 Percent

Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.

Life Sciences, Diagnostics Drive Danaher Q4 Revenues Up 11 Percent

In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year. 

Danaher Initiates 2018 Guidance

The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35. 

Danaher Completes Acquisition of Pall

Following completion of the merger with Pall, Danaher plans to split into two publicly traded companies.